Početna › Leukemija › North Carolina › Durham
Kliničke studije za Leukemija u gradu Durham, NC
13 studija za Leukemija traži sudionike na lokacijama u gradu Durham i okolici (unutar oko 30 milja). Otvorite studiju da biste vidjeli tko se može priključiti i kako kontaktirati tim studije.
Službeni tekst studije (engleski)
Tražite sudionike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
U tijeku regrutacijaFaza 3
- Quetzal Site 27, Chapel Hill · 10 mi udaljenosti
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
U tijeku regrutacijaFaza 1/2
- Duke University Medical Center, Durham
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
U tijeku regrutacijaFaza 3
- Duke University Medical Center, Durham
- University of North Carolina, Chapel Hill, Chapel Hill · 10 mi udaljenosti
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
U tijeku regrutacija
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi udaljenosti
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
U tijeku regrutacijaFaza 1/2
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill · 10 mi udaljenosti
Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi udaljenosti
Registry of Older Patients With Cancer
U tijeku regrutacijaOpažajna studija
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi udaljenosti
A Study of Revumenib and Mezigdomide in People With Leukemia
U tijeku regrutacijaFaza 1/2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mi udaljenosti
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
U tijeku regrutacijaFaza 2/3
- Duke University, Durham
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
U tijeku regrutacijaFaza 1
- Duke Blood Cancer Center, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
U tijeku regrutacijaOpažajna studija
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi udaljenosti
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
U tijeku regrutacijaOpažajna studija
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi udaljenosti
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
U tijeku regrutacijaFaza 2
- Durham VA Medical Center, Durham, NC, Durham
Studije za Leukemija u drugim gradovima
- Houston, TX28 studija
- Boston, MA25 studija
- New York City, NY19 studija
- Los Angeles, CA16 studija
- Chicago, IL16 studija
- Baldwin Park, CA12 studija
- Columbus, OH12 studija
- Nashville, TN12 studija
- Philadelphia, PA12 studija
- Milwaukee, WI11 studija
- Atlanta, GA11 studija
- Seattle, WA11 studija
Ostale studije u gradu Durham
- Rak dojke63 studija
- Rak (sve vrste)58 studija
- Nemikrocelularni karcinom pluća39 studija
- Multipli mijelom37 studija
- Metastatski karcinom33 studija
- Akutna mijeloična leukemija33 studija
- Rak pluća32 studija
- Rak prostate32 studija
- Kolorektalni rak28 studija
- Kronična limfocitna leukemija27 studija
- Rak jajnika27 studija
- Srčano zatajenje26 studija
Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.